[Current treatment strategies for diffuse large B-cell lymphoma].

Zanubrutinib monotherapy in CD79B‐mutated relapsed or refractory diffuse large B‐cell lymphoma: A multicenter Phase 2 study

Diffuse large B ‐ cell lymphoma (DLBCL) remains a clinically and molecularly heterogeneous disease, 1 with approximately one ‐ third of patients developing relapsed or refractory (R/R) disease following frontline immunochemotherapy. 2,3 Among molecularly defined sub-groups, CD79B mutations occur in 5% – 25% of DLBCL

Navigating T-Cell-Directed Therapies in Transformed Follicular Lymphoma

Simple Summary Transformed follicular lymphoma (tFL) is a subtype of diffuse large B-cell lymphoma (DLBCL) that arises from follicular lymphoma. tFL displays aggressive disease biology and is managed with intensive chemotherapy. Relapses are common, and CAR-T and bispecifics, therapies which reprogram the immune system...

Efficacy and Safety of CAR T‐Cell Therapy for Primary and Secondary Central Nervous System Lymphoma: A Systematic Review and Meta‐Analysis

Patients with relapsed or refractory primary central nervous system lymphoma (PCNSL) and secondary central nervous system lymphoma (SCNSL) have limited treatment options and poor outcomes. CD19‐directed chimeric antigen receptor (CAR) T‐cell therapy has shown promising activity in this setting; however, the available e...

[CAR-T cell therapy for acute lymphoblastic leukemia: current landscape and novel developments].

Key Challenges on the Path toward Precision Immunotherapy for Large B-cell Lymphoma.

Cell and immune therapies have transformed the outcomes of patients with lymphoma, but the majority of patients do not have durable benefit. Here, we provide our perspective on key challenges in personalizing cell and immune therapy approaches for lymphoma through discovery, validation, and clinical deployment of micro...

Precision medicine in diffuse large B-cell lymphoma: Integrating molecular biomarkers, targeted therapies, and prognostic tools

It is proposed that the future of DLBCL management lies not merely in the availability of novel agents, but in the rational sequencing and combination of these modalities based on dynamic molecular monitoring and individualized risk assessment—translating molecular insights into actionable clinical pathways.